Tocagen, a California-based clinical stage, cancer-selective gene therapy company, has named John Wood as Vice President of Regulatory Affairs and Quality Assurance.
Wood holds more than 20 years of regulatory affairs experience focusing on drugs for diseases with high unmet need. While at IDEC Pharmaceuticals he played a leading role, in collaboration with Genentech, in the first regulatory approval of Rituxan for the treatment of immune system B-cell malignancies.
Prior to joining Tocagen, Wood led regulatory affairs at Arena Pharmaceuticals. Before this he led regulatory affairs and alliance management at Amylin Pharmaceuticals.
Wood has also held regulatory leadership positions at Quintiles Consulting and Gensia.